CancerVax Aims to revolutionize Pancreatic Cancer Treatment with Innovative Immunotherapy platform
Table of Contents
Lehi, UT, December 11, 2024 (GLOBE NEWSWIRE) — CancerVax, Inc., a pioneering biotech company focused on developing a universal cancer treatment (UCT) platform, has announced its intention to target Pancreatic Ductal Adenocarcinoma (PDAC) as one of its initial preclinical advancement efforts.This aggressive form of pancreatic cancer has proven notoriously difficult to treat, leaving patients with few viable options. CancerVax’s innovative approach, which harnesses the body’s immune system to combat cancer, could offer new hope to patients and physicians alike.
The Challenge of Pancreatic ductal Adenocarcinoma
according to the American Cancer Society, an estimated 66,440 people in the United States and 515,000 globally will be diagnosed with pancreatic cancer in 2024. Of these cases, approximately 85% are PDAC, a particularly lethal form of the disease. Recent studies highlight that PDAC is “one of the most lethal diseases,with an average 5-year survival rate of less than 10%.” This grim statistic is largely attributed to the ineffectiveness of customary treatments such as chemotherapy, surgery, and radiation in significantly improving patient outcomes.
A new Approach: Leveraging the Immune System
Byron Elton, CEO of CancerVax, explained the company’s innovative strategy in a recent statement. “The body is very good at fighting well-known diseases such as measles,” he said. “After a measles infection or vaccination, the body develops lifelong immunity through immune cells like B-cells and T-cells. These cells continuously monitor for measles viruses and prevent reinfection. Our goal is to harness this natural immunity to fight cancer.”
Elton emphasized the limitations of existing cancer therapies, such as personalized cancer vaccines, which attempt to teach the immune system to recognize cancer but often yield limited success and are prohibitively expensive.“Teaching the immune system is like teaching an old dog a new trick – very difficult to do,” he noted.“Instead, we’re going to trick the dog into performing something it knows how to do very well.We believe our approach will make all the difference in using the body’s immune system to fight cancer.”
Targeting Cancer with Precision
Elton further explained that CancerVax’s ultimate objective is to enhance the accuracy of detecting, marking, and eliminating only cancer cells, while minimizing the harmful off-target effects associated with traditional treatments like chemotherapy. “Our goal is to increase our accuracy of detecting, marking and killing only cancer cells, and reducing very toxic off-target effect that other treatments such as chemo can have on the body,” he concluded.
CancerVax’s decision to focus on PDAC underscores the urgent need for more effective treatments in this area. With its groundbreaking UCT platform, the company aims to not only address the limitations of current therapies but also pave the way for a new era in cancer treatment.As research progresses, the potential impact on patients and the broader medical community could be profound.
For more information on CancerVax and its innovative approach to cancer treatment,visit www.cancervax.com.
Revolutionary Immunotherapy Approach Targets Deadly Pancreatic Cancer
A groundbreaking biotech company is harnessing the power of artificial intelligence and mRNA technology to revolutionize cancer treatment, starting with one of the deadliest forms of the disease: pancreatic ductal adenocarcinoma (PDAC).
Grant,the Principal Scientist at CancerVax,explained the company’s innovative approach in a recent statement.”When analyzing which cancer type we should target first,we utilized advanced AI tools to identify PDAC cancer cells as an ideal candidate,” he said. “These cells exhibit high expressions of a surface protein that we can effectively target, along with genetic signatures that align perfectly with our Smart mRNA technology for precise detection. Additionally, PDAC cells possess the biological mechanisms necessary to process our mRNA, making them a logical starting point.”
One of the most meaningful challenges in treating PDAC is its ability to evade the immune system. However, CancerVax’s strategy aims to overcome this hurdle by disguising PDAC cells as measles. “our theory is that by mimicking measles, the natural immune system—which is highly effective at detecting and eradicating the virus—will recognize and destroy the cancer cells,” Grant added. “This approach, combined with the limited treatment options currently available for PDAC, makes our research particularly promising. We’re thrilled about the potential to significantly enhance immunotherapy for patients battling this devastating disease.”
About CancerVax: A Vision for Universal Cancer Treatment
CancerVax is a pre-clinical biotech company dedicated to developing a universal cancer treatment platform. This platform is designed to be customizable, delivered via injection, and capable of targeting a wide range of cancer types. The company’s innovative method involves three key steps: detecting cancer cells, marking them for destruction, and utilizing the body’s natural immune system to eliminate them. By making cancer cells appear similar to well-known diseases like measles or chickenpox, CancerVax aims to leverage the immune system’s ability to combat these pathogens, effectively turning it into a powerful ally in the fight against cancer.
The ultimate goal? To make cancer treatment as simple and accessible as receiving a vaccine. “We envision a future where treating cancer is as straightforward as getting a shot,” the company stated. “It’s a better way to fight cancer, and we’re committed to making it a reality.”
To learn more about CancerVax and its groundbreaking research, visit their website at www.CancerVax.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on current beliefs, expectations, and assumptions, and involve risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. cancervax disclaims any obligation to update these statements considering new information or future events.
Contact Information
For media inquiries, please contact:
CancerVax, inc.
Phone: (805) 356-1810
Email: communications@cancervax.com
Revolutionary Immunotherapy Approach Targets Deadly Pancreatic Cancer
A groundbreaking biotech company is harnessing the power of artificial intelligence and mRNA technology to revolutionize cancer treatment, starting with one of the deadliest forms of the disease: pancreatic ductal adenocarcinoma (PDAC).
Interview with Grant, Principal Scientist at CancerVax
Senior Editor: Thank you for joining us today, Grant. Can you start by explaining why CancerVax has chosen pancreatic ductal adenocarcinoma (PDAC) as one of its initial targets?
Grant: Absolutely. PDAC is one of the most lethal forms of cancer, with an average 5-year survival rate of less than 10%. This grim statistic highlights the urgent need for more effective treatments. When we analyzed which cancer type to target first, we utilized advanced AI tools to identify PDAC cancer cells as an ideal candidate. These cells exhibit high expressions of a surface protein that we can effectively target, along with genetic signatures that align perfectly with our Smart mRNA technology for precise detection.Additionally, PDAC cells possess the biological mechanisms necessary to process our mRNA, making them a logical starting point.
The Challenge of Pancreatic Ductal Adenocarcinoma
Senior Editor: PDAC is indeed a formidable challenge.Can you elaborate on why it has proven so challenging to treat?
grant: PDAC is notoriously difficult to treat for several reasons. First, it is often diagnosed at an advanced stage when the cancer has already spread, making surgery less effective. Second,traditional treatments like chemotherapy and radiation have limited success in significantly improving patient outcomes.The disease’s aggressive nature and the lack of effective therapies make it a priority for innovative approaches like ours.
Leveraging the Immune System
Senior Editor: CancerVax’s approach is quite innovative. Can you explain how your immunotherapy platform works and why it differs from existing treatments?
Grant: Our approach is based on harnessing the body’s natural immune system to fight cancer. We aim to trick the immune system into recognizing and eliminating cancer cells, much like it does with well-known diseases like measles. Unlike personalized cancer vaccines, which attempt to teach the immune system to recognize cancer but frequently enough yield limited success, our method leverages the immune system’s existing capabilities. By enhancing the accuracy of detecting, marking, and eliminating only cancer cells, we can minimize harmful off-target effects associated with traditional treatments like chemotherapy.
targeting Cancer with Precision
Senior Editor: Precision is key in cancer treatment. How does CancerVax’s technology ensure that only cancer cells are targeted?
Grant: Our Smart mRNA technology is designed to enhance the precision of detecting and marking cancer cells. By targeting specific surface proteins and genetic signatures unique to PDAC cells, we can ensure that our treatment is highly specific. This precision allows us to minimize the harmful side effects that patients often experience with traditional treatments.Our ultimate goal is to increase the accuracy of detecting,marking,and killing only cancer cells,while reducing the very toxic off-target effects that other treatments can have on the body.
The Future of Cancer Treatment
Senior Editor: What does the future hold for CancerVax and its universal cancer treatment (UCT) platform?
grant: We are optimistic about the potential impact of our UCT platform on cancer treatment. By starting with PDAC, we aim to address one of the most challenging forms of cancer and pave the way for future advancements.our technology has the potential to be applied to a wide range of cancer types, offering new hope to patients and physicians alike. As research progresses, we believe our approach could revolutionize the way cancer is treated, ultimately improving patient outcomes and quality of life.
Senior Editor: Thank you, Grant, for sharing your insights. We look forward to following CancerVax’s progress and the potential impact of your innovative approach on the fight against cancer.
For more information on cancervax and its innovative approach to cancer treatment, visit www.cancervax.com.
